Cerebain Biotech Corp. (“Cerebain” or “the Company”), a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO) announced today it intends to hold a conference call on July 1
at 3:30 p.m. EST. The purpose of the call is to permit Dr. Surinder Saini, Chairman of the Company’s Scientific Advisory Board, an opportunity to provide the genesis of and thought processes surrounding the Company’s efforts to develop the world's first medical device specifically designed for the treatment of Alzheimer’s disease utilizing the Omentum. Investors and Analysts may join the conference call by dialing 712-432-9998, and entering access code 126307#.
About Discount Dental Materials, Inc.
Discount Dental Materials, Inc. was incorporated in Nevada on December 17, 2007. The Company’s business involves the discovery of products for the treatment of Alzheimer’s disease utilizing Omentum. The Company’s planned products include both a medical device solution as well as a synthetic drug solution. The Company’s operations are conducted through its wholly-owned subsidiary, Cerebain Biotech Corp. For more information about Discount Dental and Cerebain Biotech, please visit the Company’s website at
, under the ticker symbol “DDOO”, to view the Company’s public filings and stock quote.
Forward Looking Statements
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe,” "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.